Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders

NCT04737928 is registered in ClinicalTrials.gov with Santen Pharmaceutical (Taiwan) Co., LTD as lead sponsor.

NCT NCT04737928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04737928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders
Lead sponsor
Santen Pharmaceutical (Taiwan) Co., LTD
Phase
Not applicable
Overall status
Completed
Start date
April 2, 2018
Completion date
January 22, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, primary open angle